Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
Sponsor: Samsung Medical Center
Summary
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100000
Start Date
2024-10-22
Completion Date
2025-12-31
Last Updated
2025-07-16
Healthy Volunteers
No
Conditions
Interventions
Routine use of P-CAB on DAPT
This group received P-CAB with DAPT after PCI.
Guideline Directed Medical Therapy
This group received PPI or not with DAPT after PCI according to GI bleeding risk.
Locations (1)
Samsung Medical Center
Seoul, South Korea